Using NAD supplements to treat kidney disease in diabetes patients
Official title: NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
Funded at Brigham and Women's Hospital · NIH-10906074 · Data updated 2026-11-12
This study is looking at whether taking a supplement called NMN can help improve kidney health and lower signs of damage in people with diabetic kidney disease.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $857,882 |
| NIH project number | 5U01AG076789-03 |
| Project ID | NIH-10906074 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with diabetes and are experiencing early signs of diabetic kidney disease.
✕Less likely to help
Patients who do not have diabetes or those with advanced kidney disease may not benefit from this research.
What this research studies
This research investigates the effects of NAD augmentation through nicotinamide mononucleotide (NMN) supplementation on diabetic kidney disease (DKD). The study aims to determine if NMN can reduce urinary albumin levels, which are indicative of kidney damage, and improve overall kidney function. Participants will be randomly assigned to receive either NMN or a placebo, allowing researchers to compare the outcomes effectively. The approach is based on previous findings that suggest NAD levels are linked to kidney health and aging.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that significantly improves kidney health and reduces the risk of end-stage kidney disease in diabetic patients.
How similar studies have gone: Previous studies have shown promising results with NAD augmentation in animal models, suggesting potential for success in human trials.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Bhasin, Shalender — Brigham and Women's Hospital
- Study coordinator: Bhasin, Shalender
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
LRG1’s role in diabetic kidney disease and kidney fibrosis
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.